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ABSTRACT 101 
The COVID-19 pandemic has shaken the world since the beginning of 2020. Spain is among the 102 
European countries with the highest incidence of the disease during the first pandemic wave. We 103 
established a multidisciplinar consortium to monitor and study the evolution of the epidemic, with 104 
the aim of contributing to decision making and stopping rapid spreading across the country. We 105 
present the results for 2170 sequences from the first wave of the SARS-Cov-2 epidemic in Spain 106 
and representing 12% of diagnosed cases until 14th March. This effort allows us to document at 107 
least 500 initial introductions, between early February-March from multiple international sources. 108 
Importantly, we document the early raise of two dominant genetic variants in Spain (Spanish 109 
Epidemic Clades), named SEC7 and SEC8, likely amplified by superspreading events. In sharp 110 
contrast to other non-Asian countries those two variants were closely related to the initial variants 111 
of SARS-CoV-2 described in Asia and represented 40% of the genome sequences analyzed. The 112 
two dominant SECs were widely spread across the country compared to other genetic variants 113 
with SEC8 reaching a 60% prevalence just before the lockdown. Employing Bayesian 114 
phylodynamic analysis, we inferred a reduction in the effective reproductive number of these two 115 
SECs from around 2.5 to below 0.5 after the implementation of strict public-health interventions 116 
in mid March. The effects of lockdown on the genetic variants of the virus are reflected in the 117 
general replacement of preexisting SECs by a new variant at the beginning of the summer season. 118 
Our results reveal a significant difference in the genetic makeup of the epidemic in Spain and 119 
support the effectiveness of lockdown measures in controlling virus spread even for the most 120 
successful genetic variants. Finally, earlier control of SEC7 and particularly SEC8 might have 121 
reduced the incidence and impact of COVID-19 in our country. 122 
 123 
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The new coronavirus disease (COVID-19) caused by SARS-CoV-2 emerged in China in 126 
October/November 20191 and by the end of March of 2020 it was present in most countries of the 127 
world. The World Health Organization declared the new disease as a pandemic on 11th March 128 
2020. Spain suffered a severe epidemic with the first case notified on 29th January2 and with an 129 
accumulated number of 261,584 cases by 1st July, including 29,965 fatalities. Furthermore, a 130 
nationwide seroprevalence study showed that only one in ten cases of infection by SARS-CoV-2 131 
were diagnosed and declared in that period3, suggesting that the total number of infections has 132 
been vastly underestimated. Spain ordered a series of non-pharmaceutical intervention measures 133 
including a general lockdown on 14th March4, later applied by many other countries, and was 134 
successful in bending the curve by the end of May. Despite these measures, at least 30,000 135 
individuals died during the first wave of the epidemic and a second wave of COVID-19 slowly 136 
started by the end of July 20205. 137 
 138 
Despite the high incidence accumulated across the country some regions had significantly higher 139 
incidence than others. Genomic epidemiology and phylodynamics6–8 offer a unique opportunity to 140 
understand the early events of the epidemic at the global, regional and local levels, to track the 141 
evolution of the epidemic after its initial stages and to quantify the impact of lockdown measures 142 
on the genetic variants of the virus. However, there are challenges and caveats that prevent the 143 
use of pathogen genomes as the sole source of interpretation. While there is now a large number 144 
of SARS-CoV-2 sequences deposited in the databases9 there are still important unsampled areas 145 
of the world, including some that played an important role in the initial spread of the epidemic. In 146 
addition, the virus spreads faster than it evolves10,11 which limits the resolution of phylogenetic 147 
and phylodynamic analysis12. Finally, despite important efforts by sequencing consortiums, only 148 
a fraction of the total number of infections has been sequenced. Nevertheless, genomic 149 
epidemiology has played an important role in understanding the global and local epidemiology of 150 
COVID-1913–15. 151 
 152 
After the pandemic was declared in Spain, we assembled the National Consortium of genomic 153 
epidemiology of SARS-CoV-2 (http://seqcovid.csic.es/). This established a unique network 154 
incorporating more than 50 hospitals and scientific institutions across the country to collect clinical 155 
samples and epidemiological information from COVID-19 cases. Here we present the results of 156 
this nation-wide effort. We were able to sequence 12% of the reported cases before the national 157 
lockdown, and 1% of the reported cases of the first wave (until 14th May), including samples of 158 
SARS-CoV-2 across Spain in the early months of the pandemic (February-May). Using a 159 
combination of pathogen genomics, phylogenetic tools, clinical and epidemiological data we have 160 
been able to dissect the very early events in the dispersion of SARS-CoV-2 throughout Spain as 161 
well the evolution of the virus during the exponential phase and after the lockdown. We document 162 
simultaneous introductions in the country from multiple sources. We show that up to 40% of cases 163 
were caused by two Spanish epidemic clades, named SEC7 and SEC8. Seven other Spanish 164 
epidemic clades were detected but their role was minor, probably because they were introduced 165 
relatively close to the lockdown and had no opportunities for a rapid exponential expansion as the 166 
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initial two clades had. In contrast to other European countries these SECs belong to early lineages 167 
in the epidemic (A in Pangolin, 19B in NextStrain). We also show that the reproductive number, 168 
Re, of the most successful Spanish epidemic clades quickly declined after the implementation of 169 
lockdown measures and they were completely absent from samples taken in July-September. 170 
Our results suggest that the most successful variants were those associated with earlier 171 
introductions but also that their success may depend on the synergy between superspreading 172 
events and high mobility. These results also show the effectiveness of lockdown measures in 173 
controlling the virus spread and eliminating established successful epidemic clusters from 174 
circulation. 175 
 176 
SARS-CoV-2 was introduced multiple times from multiple sources 177 
 178 
Our dataset consists of 2,170 sequences from Spain, collected under ethical approval, from 25th  179 
February to 22nd June, coinciding with the initial phases of the COVID-19 pandemic in the country 180 
(Figure 1a). The most populated Spanish regions were sampled, resulting in a dataset with 181 
sequences representing 16 of the 17 administrative regions in which the country is divided (Figure 182 
1b). 1,962 out of the 2,170 (90.4%) samples analyzed here have been sequenced by the 183 
SeqCOVID consortium, while the remaining 208 have been generated by independent 184 
laboratories and downloaded from GISAID9 (Table S1). Spain displayed a particular viral 185 
population structure with a higher proportion of lineage A sequences compared to other European 186 
countries16(Figure 1c). Strains from patients in Spain were more closely related with cases 187 
sequenced in China and were the most abundant during the first weeks of the Spanish epidemic. 188 
They were replaced by lineage B strains (Figure S1), which differ by at least 6-7 substitutions 189 
from lineage A and dominated the beginning of the pandemic in most European countries. In 190 
addition, we observed an heterogeneous distribution of the SARS-CoV-2 genetic diversity within 191 
Spain, both at the regional and local levels. For example, our analysis shows how viral diversity 192 
declined with geographic distance from a large urban outdoor like Valencia (see Supplementary 193 
Notes). 194 
 195 
Similarly to other countries17,18, phylogenomic analyses suggest the existence of multiple 196 
independent entries of the virus into Spain. To identify possible introductions we inspected the 197 
placement of Spanish viral samples in a global phylogeny constructed with more than 30,000 198 
sequences (Figure 1d). Given the low genetic diversity of the virus, particularly at the beginning 199 
of the epidemic, we found most instances in which a Spanish sample is genetically identical to 200 
other variants circulating in the rest of the world. According to their phylogenetic placement, three 201 
different possibilities were considered for the phylogenetic position of Spanish sequences. A 202 
sequence was included in a ‘candidate transmission cluster’ when it was found in a monophyletic 203 
clade with other Spanish sequences; it was included in a ‘zero distance’ group when it grouped 204 
with other genetically identical Spanish sequences but also with other foreign sequences; and it 205 
was denoted as ‘unique’ when no matching sequence in the Spanish dataset was identified (see 206 
detailed definitions of the groups in Mat and Met and in Figure S2). We detected 224 ‘candidate 207 
transmission clusters’ comprising 827 sequences (~40% of the Spanish samples); 30 ‘zero-208 
distance clusters’, comprising 831 sequences, and 513 ‘unique’ sequences (Figures S3). Next, 209 
we determined how many unique cases and clusters were compatible with an introduction before 210 
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the general lockdown. We detected that 191 groups (165 'candidate transmission clusters’ plus 211 
26 ‘zero distance clusters’) and 328 unique sequences met this criteria, representing at least 519 212 
independent introductions (distribution of dates in Figure 1e). This is probably an underestimation 213 
of the total number of entries because the number of sequences analyzed is a small subset of the 214 
total notified cases (Figure 1a). Phylogenetic analysis suggests that the most likely introductions 215 
of cases with a clear phylogenetic link (see Methods) came from Italy, the Netherlands, England, 216 
and Austria (accounting for ~23%, ~20%, ~13% and 12% of the cases for which a likely country 217 
of origin can be inferred, respectively) (Figure 1f). The observation that more than half of the 218 
introduction events detected are unique sequences illustrates the heterogeneous outcome after 219 
an introduction, as some events resulted in large epidemiological clusters, and others 220 
disappeared leaving almost no trace.  A clear example is the first described death in Spain for 221 
which we have generated a partial sequence and who was infected in Nepal but who did not 222 
generate any identifiable secondary cases in our dataset.  223 
 224 




Figure 1. SARS-CoV-2 sequenced genomes from Spain. a. Distribution of sequenced samples 229 
(blue) versus confirmed cases in Spain (grey) by date. Country lockdown measures were in effect 230 
from 13th March to 17th May 2020. b. Distribution of the sequenced samples across Spain was 231 
plotted in Microreact. This data can be explored with more detail in the Microreact webpage 232 
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(https://microreact.org/showcase) loading the Data S1 files. The size of each piechart correlates 233 
with the number of sequences collected in the corresponding area. Each color corresponds to a 234 
specific Pangolin lineage, as detailed in Figure S1 (light yellow and green correspond to lineage 235 
A, all the others are lineage B). c. Distribution of majorSARS-CoV-2 clades during the first stages 236 
of the pandemic (before 1st April 2020), in those European countries with more than 50 sequences 237 
deposited in GISAID  13th November 2020. d. Global maximum likelihood phylogeny constructed 238 
with 32,416 sequences, placement of Spanish samples is indicated in red. e. New and 239 
accumulated introductions to Spain. Lower-bound introduction estimates were defined as the date 240 
of the likely infection of the first case in a cluster (14 days before symptom onset). f.  Estimated 241 
international origin of SARS-CoV-2 introductions based on phylogenetic data; in color, those 242 
countries with a likely contribution larger than 10%. 243 
 244 
A few genetic variants dominated the first wave in Spain 245 
To identify those introductions that resulted in sustained transmission and therefore 246 
epidemiologically successful in the long-term, we scanned the phylogeny for larger clades mainly 247 
composed by Spanish samples (see Mat and Met for criteria). We identified 9 Spanish Epidemic 248 
Clades (SEC) distributed across the phylogeny, representing 46% of the total Spanish dataset 249 
analyzed (995 out of 2,170 samples) (Figure 2a,  Figure S4, Figure S5, Table S1, Table S2). We 250 
first noticed that only two SECs encompassed 30% and 10% of all Spanish samples (SEC8 and 251 
SEC7, respectively). This implies that the introduction of these two specific genetic variants 252 
explains a high proportion of the entire epidemic for the first wave in the country. In fact, they were 253 
responsible for 44% of the ‘candidate transmission clusters’ identified before the lockdown (Figure 254 
2b). We then estimated the time of introduction in Spain for the 9 SECs using a Bayesian 255 
approach (Table S2). As a conservative estimate we considered the time of introduction as any 256 
time between the age of the most recent common ancestor of the SEC and the date of the first 257 
Spanish sample (Figure 2c). Thus, we assume that the ancestor of the SEC was not necessarily 258 
in Spain.  259 
 260 
Our analysis shows that the earlier the introduction, the larger the size of the SEC (Figure S6). 261 
The larger clades, SEC7 and SEC8, were the first successful genetic variants introduced into 262 
Spain during late January - February (Figure 2b). Both belong to lineage A (Pangolin 263 
nomenclature) and partially explain the peculiar population structure in Spain relative to other 264 
European countries (Figure 1c). In addition, compared with other SECs, SEC7 and SEC8 were 265 
widely spread in the country, being present in at least 10 of the 17 administrative regions (Figure 266 
2b) and had a mean pairwise geographic distance between samples of more than 300 km 267 
regardless whether or not the Islas Canarias and Baleares are included (Figure S7). On the 268 
contrary, SECs that were introduced later were smaller and showed a narrower geographic 269 
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Figure 2. Inferred introduction times and expansion of SECs. a. Maximum likelihood 277 
phylogenetic tree of Spanish sequences indicating the identified Spanish Epidemic Clades 278 
(SECs). b. Range of dates for each ‘candidate transmission cluster’ identified within the SECs, 279 
and the most probable origin date (14 days before the first documented case) c. Time of the Most 280 
Recent Common Ancestors (MRCA) of each SEC is plotted, including the 95% HPD interval (High 281 
Posterior Density). First collected sample is indicated and pointed if it is Spanish or not. d. SEC 282 
dispersion through the different regions of the country. Some SECs are circumscribed to one or 283 
two regions, while some others have expanded through the complete territory. 284 
 285 
 286 
Superspreading events and mobility were key for  the success of SEC8  287 
Why some genetic variants succeed over others cannot be answered solely from genomic 288 
sequence data. We must also take into account the epidemiological dynamics in the country. 289 
There is data supporting a role of the 614G mutation in the spike protein associated with 290 
epidemiological success. However, SEC7 and SEC8 do not harbour the variant, explaining why 291 
614G was less frequent during the first weeks of the epidemic in Spain than in other countries 292 
(Figue S8). In addition, the inspection of signature positions for both SECs did not lead to any 293 
likely genomic determinant of epidemiological success (Table S3). Alternatively, we have 294 
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9 
investigated linked epidemiological data from the earliest cases to shed light on the early success 295 
of SEC8.  296 
In a first phase, SEC8 was introduced at least twice from Italy to the city of Valencia (Figure 3a). 297 
There is epidemiological evidence that both cases were infected in Italy, as they attended the 298 
Atalanta-Valencia Champions League football match on 19th February, and that one of them 299 
initiated a transmission chain upon returning to Valencia a few days later. This epidemiological 300 
link strongly suggests that the SEC8 genetic variant was imported from Italy. This  introduction 301 
occurred in agreement with the estimated time of entry of SEC8 into Spain (Table S2). NextStrain 302 
tracking tools for viral spatial spread suggests additional SEC8-related early seedings in Madrid, 303 
País Vasco, Andalucía, and La Rioja regions (Video S1) which may involve other countries, not 304 
necessarily Italy. Given the lack of virus genetic differentiation and scarce epidemiological 305 
information there is no certainty on whether they resulted from independent introductions from 306 
abroad or from internal migrations of infected persons, although the simultaneous detection in 307 
different regions favours the first option. Most of these multiple introductions occurred during the 308 
second half of February, a period in which more than 11,000 daily entries of travelers from Italy 309 
were recorded. 310 
In a second phase, SEC8 was fueled by superspreading events. Based on the topology of the 311 
phylogenetic tree (Figure 2a) there were multiple clades involving a large number of very closely 312 
related sequences (1-3 SNPs) (Figure 3a). Of special relevance was a funeral on 23rd February 313 
with attendees from the País Vasco and La Rioja regions from which 25 sequences had been 314 
sequenced. Importantly, although they did not differ by more than 2 SNPs these sequences are 315 
spread across the SEC8 phylogeny suggesting the existence of many more non-sampled 316 
secondary cases across the country (Figure 3a). In a third phase, SEC8, after reaching high 317 
frequency locally, was redistributed across the country and in less than two weeks it reached a 318 
prevalence of 60% among the sequenced genomes (Figure 3b),  being present in almost every 319 
region analysed. All these phases occurred between the first known diagnosed SEC8 case on 320 
25th February (Table S2) and the lockdown on 14th March, highlighting the need for very early 321 
containment measures to stop the spread of SARS-CoV-2. 322 
Effect of lockdown on the major clades 323 
In the second half of March, Spain imposed a strict lockdown on non-essential services and 324 
movements. A Bayesian birth-death skyline analysis allowed us to evaluate the impact of the 325 
lockdown on the effective reproductive number (Re) of the most successful SECs. The analyses 326 
of SEC7 (Figure S9) and SEC8 (Figure 3c) resulted in similar estimates for Re before the lockdown 327 
(2.10 with 95% highest posterior density, HPD:1.67-2.62 and 3.14 HPD: 2.71-3.57, respectively) 328 
similar to the Re estimated early in the epidemic for SARS-CoV-219,20. After the lockdown there 329 
was a substantial decrease to less than 0.5 in both cases (0.27 95% HPD: 0.06-0.47; 0.23 HPD: 330 
0.15-0.32, respectively). The model also estimated that the date with highest support for a change 331 
in Re roughly coincides with the start of the lockdown in Spain on 14th March (20th March HPD: 332 
15-25th March; 9th March HPD: 8-10th March, respectively). In addition, we calculated the doubling 333 
time for both SECs21. Before the corresponding date of change for Re, the doubling time for SEC7 334 
was estimated at 6.3 days (95% HPD: 4.3-10.2 days) and that for SEC8 at 3.3 days (95% HPD: 335 
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2.7 - 4.1 days). Re values after those dates had a posterior distribution that did not include 1.0 for 336 
both SECs (see Supplementary Notes), a result that supports the reduction in the rate of increase 337 
of confirmed cases and that is in agreement with estimates from epidemiological models and 338 
data19,20. 339 
 340 
Figure 3. SEC8 epidemiological success and impact of mobility restrictions. a. Maximum 341 
likelihood phylogeny with all the strains of SEC8. Samples with epidemiological evidence about 342 
their origin are marked in the tree. In red, cases imported from different events in Italy. In orange, 343 
secondary cases originated from one of the cases introduced from Italy (also marked with blue 344 
arrows). In purple, cases related to a large burial in La Rioja. Green stars mark potential 345 
superspreading events of more than 10 sequences sharing at least one clade-defining SNP. b. 346 
Contribution of SEC8 to the total of samples sequenced over time. The horizontal red line marks 347 
the start of the Spanish lockdown, on 14th March. c. Phylodynamic estimates of the reproductive 348 
number (Re) of SEC8. The X axis represents time, from the origin of the sampled diversity of 349 
SEC8 to the date of the last collected genome on 16th May. The blue dotted line shows the 350 
posterior value of the timing of the most significant change in Re, around 9th March [95% HPD: 351 
8–10th March]. The Y axis represents Re, and the violin plots show the posterior distribution of this 352 
parameter before and after the change time in Re, with a mean of 3.14 [95% HPD: 2.71-3.57] and 353 
0.23 [95% HPD: 0.15-0.32] before and after the change time respectively. The phylogenetic tree 354 
in the background is a maximum clade credibility tree with the tips colored according to whether 355 
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Our analyses have revealed more than 500 independent introductions of SARS-CoV-2 to Spain 360 
between late January, coinciding with the first reported cases in our country2,22, and mid-April 361 
2020. The earliest entries corresponded to lineage A, matching the virus diversity profile reported 362 
for the country. This lineage was common in Asia but rare in the rest of Europe23. We observed 363 
that two genetic variants (SEC7 and SEC8) of this lineage dominated the first stages of the 364 
epidemic wave in Spain contrary to what was observed in other European countries. In fact, most 365 
cases described in Europe at the beginning were lineage B what makes the situation in Spain 366 
more unique. This highlights the importance of epidemiological data in which we know that SEC8 367 
was introduced at least from Italy contradicting the dominant lineages in the country at that 368 
time16,24,25. 369 
 370 
Reasons for why some variants dominate over others can be related to the viral genetics, to 371 
founder events associated to particular variants, and to the implementation of different measures 372 
over time, not necessarily in an exclusive manner. This variant distribution could also be partly 373 
explained by sampling bias. No mutation likely associated with epidemiological success has been 374 
identified in our analyses of SEC7 and SEC8 (Table S3). In fact, neither SEC7 nor SEC8 carry 375 
the 614G mutation in the spike protein contrary to what is seen in most, but not all, lineage B 376 
variants (Figure S8). The mutation 614G has been associated with increased viral shedding 377 
compared to the ancestral 614D variant in laboratory conditions26 and in transmission studies27,28. 378 
However, other studies cast doubts on its actual role in the epidemic29 suggesting that  its impact 379 
on epidemic transmission was minor, if any. In the case of Spain, 614G was not behind the initial 380 
success of the epidemic because SEC7 and particularly SEC8 were much more common than 381 
other genetic variants until the lockdown (10% and 30% of cases respectively). On the contrary, 382 
founder events seem to have played an important role for these particular variants. Our analysis 383 
shows that they were the first variants introduced in the country and, at least SEC8, were linked 384 
to very early superspreading events that contributed to their success. However, an early 385 
introduction of lineage A variants also occurred in other European countries but they did not take 386 
hold and were displaced by lineage B. Despite the early adoption of strong NPI measures, we 387 
hypothesize that epidemic control in the first wave in Spain was soon overwhelmed as compared 388 
to countries that controlled early outbreaks13. This was likely associated with a strict 389 
implementation of the case definition by the WHO, which allowed a stealth dispersion of the first 390 
introductions, but also to several superspreading events, which strongly favoured the 391 
establishment of the earliest variants arriving into the country. Spain implemented one of the most 392 
strict lockdowns in Europe with a high compliance from the population as tracked by mobility 393 
data30. The efficacy of NPI measures was evident a few weeks later and it was reflected in the 394 
almost complete elimination of SEC7 and SEC8 by the end of the first wave. The spread of new 395 
variants, represented by other SECs and more isolated cases, corresponded to a new phase in 396 
the epidemic at the national level, with much more limited mobility and social interactions which 397 
prevented the establishment of large clusters and transmission chains except in high risk settings 398 
such as nursing-homes and long-term care facilities. 399 
  400 
This study has several limitations. Despite being one of the countries with more contribution to 401 
public repositories, our dataset only represents a small subset of confirmed cases that occurred 402 
in the first COVID-19 wave (1% of cases). Moreover, sampling across the country was 403 
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heterogeneous and the representation of each region in the dataset was not always proportional 404 
to the incidence during the studied period. Lack of genome data from countries with high disease 405 
burden, especially at the beginning of the pandemic, may have led to underestimating the total 406 
number of introductions and prevented a reliable identification of their likely sources based only 407 
on viral genome sequences. In addition, we did not have access to individual patient data for most 408 
cases. Despite these limitations, we have been able to investigate some of the key cases and 409 
events that ignited the epidemic in Spain. This allowed us to understand the origin and early 410 
spread of SEC8, which would not have been possible based only on genome data. But we have 411 
also shown that genetic data can be used to accurately estimate relevant epidemiological 412 
parameters such as Re and doubling times even when the proportion of sampling is low. 413 
 414 
We believe that our results allow us to draw lessons for the control of this and future pandemics. 415 
First, we have shown how specific variants can be used to track the effectiveness of epidemic 416 
control measures. In February, the number of SEC8 cases was just a few dozens and yet it ended 417 
up accounting for 60% of the sequenced samples in the first weeks of March. Second, the closure 418 
of borders to countries with high incidence is relevant to reduce simultaneous and multiple imports 419 
of the virus, but its efficacy depends on the inward incidence of the disease31. The most successful 420 
SECs during the first wave were probably those that arrived early, multiple times, and to diverse 421 
locations. Thus, as suggested elsewhere, founder effects are important for the success of certain 422 
variants. Third, SEC7 and SEC8 extended across Spain in a matter of days. Controlling mobility 423 
is essential when the level of community transmission is high, as demonstrated by the significant 424 
decrease in Re for these high-transmission genetic variants after the lockdown. As a comparison, 425 
before the lockdown Re values were 50% higher in Spain (3.3 for SEC8) than in Australia (1.63), 426 
and they underwent a reduction down to 7% of the original value (0.23) as a result of the 427 
containment measures, compared to 30% (0.48) in Australia15. From a public health perspective, 428 
our results add to the evidence that the success of specific genetic variants is fueled by 429 
superspreading events which rapidly increase the prevalence of the virus32. Subsequently, 430 
coupled to the high mobility of our connected world, a variant may end up dominating the epidemic 431 
in a geographic location. This is what occurred to SEC8 and what at a local level has been 432 
described in Boston33. In fact, we have recently described a new variant in Europe that is rapidly 433 
growing in several countries, which is also linked to initial superspreading events34. The 434 
conclusion is that early diagnosis and notification of cases would have helped to a timely 435 
implementation of effective contact tracing that, coupled with earlier mobility closures and maybe 436 
tighter border control,  would have probably delayed a few days the expansion of genetic variants 437 
such SEC8 during the early stages of the epidemic in Spain. Whether this might have changed 438 
the global shape of the epidemic in the country or other genetic variants would have performed 439 
its role leading to a similar outcome cannot be ascertained, but the comparison with other 440 
countries lead us to suspect that there would have been not many differences with them.  441 
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oldest MRCA date and the first Spanish collected sample. Number of "candidate 534 
transmission clusters", "zero distance clusters" and "unique" included in each SEC 535 
are mentioned. “MRCA2” indicates the time of the previous ancestor to the MRCA, 536 
considering only nodes that display a posterior probability higher than 0.5. If we 537 
consider that the MRCAs were already in Spain, then the introductions into the 538 
country occurred between the MRCA2 and the MRCA dates. 539 
- Table S3: SEC definitory mutations. 540 
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to be plotted using the Microreact server. 542 
- Video S1: Video showing the transmission dynamics of SEC8 within Spain from 543 
2020-01-16 to 2020-07-19, obtained from NextStrain. 544 
-  Supplementary Figures 545 
 -Figure S1: Abundance of the different Pangolin lineages in the dataset by epidemiological 546 
week (number of weeks since 2019-12-23) as plotted in Microreact. 547 
 -Figure S2: Examples of the different groups of sequences identified. ‘Candidate 548 
transmission clusters’ are groups of Spanish sequences that form a clade. ‘Zero distance clusters’ 549 
are groups of Spanish sequences that are at zero distance from each other. Finally, the ‘unique’ 550 
sequences are Spanish sequences that are more than 1 SNP away from any other Spanish 551 
sequence and that do not share a most recent common ancestor (MRCA) node with other Spanish 552 
sequences 553 
 -Figure S3: Distribution of the different clusters/groups sizes in Spanish samples. 554 
 -Figure S4: Number of international and Spanish sequences in each SEC. 555 
 -Figure S5: Phylogenetic location of each SEC in the global SARS-CoV-2 phylogeny. 556 
Sequences from Spain are coloured according to their SEC (as indicated in Figure 2) while 557 
international sequences remain in black colour.  558 
 -Figure S6: Time of the MRCA of each SEC plotted against the contribution of each SEC 559 
to the total number of samples in the Spanish dataset. We observed a significant correlation (⍴=-560 
0.69, p-value=0.03) between the time of the MRCA of each SEC and its size, estimated as the 561 
number of samples sequenced. 562 
 -Figure S7: Distribution of genetic (salmon) versus geographic (grey) distances within 563 
each pair of samples belonging to the same SEC. 564 
 -Figure S8: Distribution of sequences harbouring the 614G mutation (blue) versus the 565 
614D mutation (salmon,wild-type) in the S gene for the spanish sequences in our dataset. In the 566 
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left panel, a histogram of samples sorted by date of sequencing. At right, frequency of both 567 
mutations in the sequenced samples by date. The national lockdown event is marked by a purple 568 
vertical line.  569 
-Figure S9: Phylodynamic estimates of the effective reproductive number (Re) of Spanish 570 
SEC7. A birth–death skyline (BDSKY) model was implemented in Beast v.2, allowing for 571 
piecewise changes in Re, with the time and magnitude estimated from the data. The X axis 572 
represents time, starting with the MRCA of all sampled diversity within SEC7 and ending with the 573 
date of the most recently sequenced genome from 15th May. The blue dotted line indicates the 574 
posterior value of the timing of a most significant decrease in Re, around 20th March [95% HPD: 575 
15–25th March]. The Y axis represents Re, and the violin plots show the posterior probability 576 
distribution for this parameter before and after the change time in Re; with a mean of 2.10 [95% 577 
HPD: 1.67–2.62] and 0.27 [95% HPD:0.06–0.47] before and after this time, respectively. The 578 
phylogenetic tree in the background is the maximum clade credibility tree from the BDSKY 579 
analysis, with the tips colored according to whether they were sampled before or after 20th March. 580 
- Figure S10: Mean pairwise genetic distance vs geographic distance (in SNP number), 581 
between the largest cities (> 70k inhabitants) of the Comunidad Valenciana autonomous region. 582 
- Figure S11: Left) Heatmap of genetic diversity for the province of Valencia; red colors 583 
indicate high diversity; blue colors indicate lower diversity. Genetic diversity has been measured 584 
as the number of base substitutions per site averaged over all sequence pairs within each 585 
municipality. Genetic diversity is largest near Valencia,  the region’s capital, and decreases with 586 
geographic distance to it. Right) All sequences included in our dataset from Comunidad 587 
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